Department of Otorhinolaryngology Head and Neck Surgery, Gansu Provincial Hospital, Lanzhou City, Gansu Province, PR China.
The First Clinical Medical College of Lanzhou University, Lanzhou City, Gansu Province, PR China.
Life Sci. 2021 May 15;273:119307. doi: 10.1016/j.lfs.2021.119307. Epub 2021 Mar 8.
The human epidermal growth factor receptor (HER) family gene is involved in a wide range of biological functions in human cancers. Nevertheless, there is little research that comprehensively analysis the correlation between HER family members and prognosis, tumor microenvironment (TME) in different cancers.
Based on updated public databases and integrated several bioinformatics analysis methods, we evaluated expression level, prognostic values of HER family gene and explore the association between expression of HER family gene and TME, Stemness score, immune subtype, drug sensitivity in pan-cancer.
EGFR, ERBB2, ERBB3, and ERBB4 were higher expressed in four cancers, five cancers, ten cancers, and two cancers, respectively. HER family gene expression is related to the prognosis in several cancers from TCGA and has a significant correlation with stromal and immune scores in pan-cancer also has a significant correlation with RNA stemness score and DNA stemness score in pan-cancer. Expression level of HER family gene is associated with immune subtype in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma. EGFR expression was negatively associated with drug sensitivity of Pipamperone, Tamoxifen, Bafetinib and positively related to drug sensitivity of Dasatinib and Staurosporine. ERBB2 expression was negatively related to drug sensitivity of Ifosfamide, Imexon, and Oxaliplatin. ERBB4 expression was positively related to drug sensitivity of E-7820.
These findings may elucidate the roles played by HER family gene in cancer progression and providing insights for further investigation of the HER family gene as potential targets in pan-cancer.
人类表皮生长因子受体（HER）家族基因参与人类癌症的广泛生物学功能。然而，几乎没有研究全面分析 HER 家族成员与不同癌症中的预后、肿瘤微环境（TME）之间的相关性。
基于更新的公共数据库并整合了几种生物信息学分析方法，我们评估了 HER 家族基因的表达水平和预后价值，并探索了 HER 家族基因表达与 TME、干性评分、免疫亚型、泛癌药物敏感性之间的关联。
EGFR、ERBB2、ERBB3 和 ERBB4 在四种癌症、五种癌症、十种癌症和两种癌症中的表达分别更高。来自 TCGA 的几种癌症中，HER 家族基因表达与预后相关，并且与泛癌中的基质和免疫评分显著相关，也与泛癌中的 RNA 干性评分和 DNA 干性评分显著相关。HER 家族基因的表达水平与头颈部鳞状细胞癌和肾透明细胞癌中的免疫亚型相关。EGFR 表达与 Pipamperone、Tamoxifen、Bafetinib 的药物敏感性呈负相关，与 Dasatinib 和 Staurosporine 的药物敏感性呈正相关。ERBB2 表达与 Ifosfamide、Imexon 和 Oxaliplatin 的药物敏感性呈负相关。ERBB4 表达与 E-7820 的药物敏感性呈正相关。
这些发现可能阐明了 HER 家族基因在癌症进展中所起的作用，并为进一步研究 HER 家族基因作为泛癌中的潜在靶点提供了思路。
